MedTrace Logo

CHANCE - Candesartan in Hypertrophic Cardiomyopathy

NCT00430833 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2007-02-02

No results posted yet for this study

Summary

The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.

Conditions

Interventions

DRUG

candesartan

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Martin Penicka, PhD · Charles University, Prague, Czech Republic

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430833 on ClinicalTrials.gov